Navigation Links
Abingworth Appoints David Mayer as Partner

LONDON and BOSTON, April 29 /PRNewswire/ -- Abingworth, the international life sciences investment group, today announced the appointment of David Mayer as Partner. He will be based at the Company's offices in Waltham, MA, USA and his prime responsibility will be to support Abingworth's efforts in growth equity, which will include expansion and acquisition financings, small buyouts and build-ups in healthcare and life science companies. Abingworth plans to invest from 10 million pounds Sterling ($20 million) to up to 40 million pounds ($80 million) in each of its growth equity investments.

Mr. Mayer adds significant depth and expertise to Abingworth with more than 12 years experience in growth equity/buyouts, of which 8 years have been spent focused on the healthcare sector. Mr. Mayer was most recently a Managing Partner at Thoma Cressey Equity Partners (TCEP). He was one of five Managing Partners at TCEP, which managed more than $1.75 billion in capital, and he opened their Boston office in 2004. He was also responsible for expanding the areas within healthcare in which the firm now invests to include pharmaceuticals and medical products, in addition to healthcare services. Notable investments made during his time at TCEP include: ESP Pharma, Inc., Jazz Pharmaceuticals, Inc., Critical Care Systems, Inc., Essent Healthcare, Inc. and Continuing Care RX, Inc.

"We are delighted to welcome Dave to our investment team," said Stephen Bunting, Managing Partner of Abingworth. "He has a proven track record in growth equity and has served on the boards of several healthcare and life science companies. His broad network of contacts and extensive experience will provide valuable strategic support to our investment process and to our portfolio companies. We believe he is an excellent fit with our organization."

David Mayer said, "I am very pleased to be joining Abingworth, one of the pioneering investment firms in the life sciences area, and I look forward to being able to contribute my experience to help identify and develop growth equity opportunities for the firm."

About Abingworth

Abingworth is an international life sciences investment group active on both sides of the Atlantic with offices in London, Menlo Park (California) and Boston. Founded in 1973, the Company invests across all stages of development, including early-stage, growth equity and quoted companies in the healthcare and life sciences sectors. Abingworth has funds under management of over $1.25 billion.

SOURCE Abingworth
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MIGENIX Appoints Pieter Dorsman to Board of Directors
2. Anavex appoints Dr. Dimitri Goundis to lead Clinical Development
3. Phytomedics Inc. Appoints Dr. Laurie Smaldone Alsup, MD., as President and Chief Executive Officer
4. Metabolex Appoints Donald Hill as Chief Financial Officer
5. Biopure Appoints New Independent Auditor
6. Indivumed Appoints Annette Kassen as Vice President Clinical Research
7. ADVENTRX Appoints Vice President of Manufacturing
8. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
9. NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
10. Observant LLC Appoints Two New Directors to the Senior Management Team
11. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
Post Your Comments:
(Date:10/13/2015)... NEW YORK , October 13, 2015 ... biotechnology acceleration and development company, has entered into a ... New York and Paris, France ... --> --> This collaborative ... a highly respected scientific advisory team as well as ...
(Date:10/13/2015)... TORONTO , Oct. 13, 2015  Generex Biotechnology ... has entered into a non-binding Letter of Intent (LOI) with ... that has developed a proprietary cooling technology designed to improve ... the United States and three million ... of 25 and 44 diagnosed as infertile.  For 42% of ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... focused ultrasound (HIFU) technologies, announced today that it received de novo clearance from ... in the U.S. for the ablation of prostate tissue. Sonablate® is the first ...
(Date:10/13/2015)... 13, 2015 the United States ... .  PRCC represents about 14% of all new cases of kidney ... Canada and Europe . ...   --> Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) ... and AstraZeneca AB (publ) ("AstraZeneca") have completed enrolment in a global ...
Breaking Biology Technology:
(Date:9/30/2015)... 30, 2015  The global glucose monitoring device and diabetes ... says a new report on the industry from Kalorama Information. Sales ... the market, followed by continuous glucose monitoring and sensor segment, ... market for these products in its latest report, The ... , ...
(Date:9/28/2015)... NEW YORK , Sept. 28, 2015 ... platform, announced today that its expedited traveler ...  CLEAR,s innovative platform transforms travel, bringing a ... for its members. "CLEAR offers ... which enhances customer service," said Jim ...
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
Breaking Biology News(10 mins):